MEDINCELL
LIVE

Serial Number

88404359

Owner

MedinCell S.A.

Attorney

Stephen P. McNamara

Filing Date

Apr 26, 2019

Add to watchlist:

No watchlists yet
View on USPTO

MEDINCELL Trademark

Serial Number: 88404359 • Registration: 6077767

MEDINCELL is a trademark filed by MedinCell S.A. on April 26, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

MedinCell S.A. (5 trademarks)

3 rue des Frères Lumière

Entity Type: 98

Trademark Details

Filing Date

April 26, 2019

Registration Date

June 16, 2020

Published for Opposition

March 31, 2020

Goods & Services

Pharmaceutical preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical preparations, namely, a drug delivery system comprising pharmaceutical compositions for subcutaneous or intraarticular administration for the continuous release of therapeutic agents for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations, namely, a drug delivery system comprising compositions that facilitate continuous release delivery of a wide variety of therapeutic subcutaneous or intraarticular veterinary agents; pharmaceutical compositions for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate controlled release delivery of subcutaneous or intraarticular active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical and veterinary pharmaceutical preparations; sustained or extended release drug delivery agents being compounds used to facilitate delivery of drugs, sold as an integral component of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Carriers and mediums being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary pharmaceutical preparations and substances for subcutaneous delivery for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders

Filing History

TEAS SECTION 8 & 15 RECEIVED
Jun 23, 2026 E815
TEAS SECTION 8 & 15 RECEIVED
Jun 3, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 16, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Jun 16, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 31, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 31, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 11, 2020 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Feb 27, 2020 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 7, 2020 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 31, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 31, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 31, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 31, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 8, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 10, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jul 10, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jul 10, 2019 CNRT
ASSIGNED TO EXAMINER
Jul 9, 2019 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
May 23, 2019 AMPX
ASSIGNED TO LIE
May 19, 2019 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
May 13, 2019 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 13, 2019 NWOS
NEW APPLICATION ENTERED
Apr 30, 2019 NWAP